TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis C$1.30 -0.03 (-2.26%) (As of 09/6/2024 ET) Add Compare Share Share Today's RangeC$1.25▼C$1.3650-Day RangeC$1.25▼C$1.4952-Week RangeC$1.20▼C$3.23Volume57,945 shsAverage Volume54,299 shsMarket CapitalizationC$99.92 millionP/E RatioN/ADividend Yield0.31%Price TargetC$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Oncolytics Biotech alerts: Email Address Oncolytics Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.8% UpsideC$3.00 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.46 out of 5 stars 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has received no research coverage in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ONC. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth.Read more about Oncolytics Biotech's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONC. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 3 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.82% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 1.77% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Oncolytics Biotech Stock (TSE:ONC)Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Stock News HeadlinesAugust 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncolytics Biotech with Promising Developments in Cancer Therapy TrialsAugust 17, 2024 | theglobeandmail.comExtending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast CancerSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 12, 2024 | marketwatch.comSernova Names Jonathan Rigby as New CEOAugust 4, 2024 | investing.comEarnings call: Oncolytics Biotech outlines progress in cancer trialsJuly 26, 2024 | baystreet.caIntegrated Cyber Solutions IncJuly 24, 2024 | theglobeandmail.comClosing Bell: Oncolytics Bio flat on Tuesday (ONC)July 23, 2024 | finanznachrichten.deBioInvent International: BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMOSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.May 15, 2024 | finance.yahoo.comOncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer TrialMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed on Oncolytics Biotech’s Advancements and Prospective Partnerships in Cancer Treatment PipelineMay 11, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)May 10, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational HighlightsMay 9, 2024 | msn.comONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024May 9, 2024 | finanznachrichten.deFN Media Group: Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036May 9, 2024 | ca.finance.yahoo.comStocks in play: Oncolytics Biotech Inc.May 9, 2024 | finance.yahoo.comOncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational HighlightsMay 9, 2024 | finanznachrichten.deUSA News Group: Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbSee More Headlines Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ONC CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.00 High Stock Price TargetC$3.00 Low Stock Price TargetC$3.00 Potential Upside/Downside+130.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-138.22% Return on Assets-71.33% Debt Debt-to-Equity Ratio6.09 Current Ratio4.99 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.31 per share Price / Cash Flow4.22 Book ValueC$0.24 per share Price / Book5.42Miscellaneous Outstanding Shares76,860,000Free FloatN/AMarket CapC$99.92 million OptionableNot Optionable Beta1.38 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentMs. Amy Goodowitz Levin B.S.N.R.N., Vice President of Clinical OperationsJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen BBAC.M., FCA, LLD, MBA, ConsultantMore ExecutivesKey CompetitorsProMetic Life SciencesTSE:PLIVIVO CannabisCVE:ABCNEmblemCVE:EMCFennec PharmaceuticalsTSE:FRXMedicenna TherapeuticsTSE:MDNAView All Competitors ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncolytics Biotech's stock was trading at C$1.79 at the start of the year. Since then, ONC stock has decreased by 27.4% and is now trading at C$1.30. View the best growth stocks for 2024 here. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (TSE:ONC) released its earnings results on Thursday, August, 1st. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI) and Bombardier (BDRBF). This page (TSE:ONC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONC Stock Alerts